NCT02558959

Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer

Effect of Second-line Irinotecan and Capecitabine Versus Irinotecan Alone in Advanced Biliary Tract Cancer Patients Progressed After First-line Gemcitabine and Cisplatin: A Randomized Controlled Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 64 (actual)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to investigate the effect of second-line irinotecan and capecitabine versus irinotecan alone for gemcitabine and cisplatin refractory advanced biliary tract cancer patients.

Conditions

• Biliary Tract Neoplasms

Interventions

Type	Name	Description
DRUG	Irinotecan
DRUG	Capecitabine

Timeline

• Start date: 2015-09-01
• Primary completion: 2017-09-30
• Completion: 2017-12-31
• First posted: 2015-09-24
• Last updated: 2018-02-13

Locations

1 site across 1 country: China